Designing precision binders for amyloid diseases
We design novel biologics with AI and validate them in our own lab, focusing on the hardest unsolved problems in amyloid biology.
Bring precision therapies for amyloid diseases to patients faster.
We design and validate binders that recognize the specific amyloid structures behind each disease. We advance them as therapeutics and diagnostics, in-house and with pharma and biotech partners.
Generative AI paired with an accelerated lab.
We design binders in silico, then produce and test them in short cycles, selecting for polymorph specificity rather than pan-amyloid binding.
How it worksFour programs across Alzheimer’s, Parkinson’s and ATTR.
Our tau fibril program is in candidate selection with UC Santa Barbara, alongside tau FIA in lead optimization and discovery programs for α-synuclein and TTR.
View our pipelineThe design platform we use, available to researchers.
De novo antibody design, 3D structure visualization and project management in the browser, with private enterprise deployments.
Explore the platform
Computational design and wet-lab validation under one roof.
A Santa Barbara team combining computational biophysics with wet-lab automation and antibody translation.
Meet the teamGet in touch with us
Have a difficult amyloid target, or interested in licensing one of our programs? We want to hear about it.
+1 (805) 714-9560
